Science-Backed: 8,500 Steps Daily for Sustainable Weight Loss
A new analysis reveals that walking 8,500 steps per day helps sustain weight loss after diet-based programs. Researchers found participants lost nearl...
Xeber.world
weight loss
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Hims Reports $33M Loss Amid Shift to GLP-1 Weight Loss Drugs
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Could Rival Zepbound for Obesity and Liver Disease Treatment
Survodutide, a next-generation GLP-1 drug, achieved a 16.6% reduction in body weight in a Phase 3 trial, outperforming placebo by over 13%. The dual-a...
Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
FDA Approves Higher Dose Wegovy Injection for Enhanced Weight Loss Results
The FDA has approved a 7.2 mg weekly dose of Wegovy, a GLP-1 medication, for weight loss. Clinical trials show this higher dose can lead to 25% more w...
Study Finds Repeating Meals Boosts Weight Loss Success
A recent study reveals that eating the same meals daily may lead to greater weight loss compared to varied diets. Researchers found that consistent ca...
Intermittent Fasting Boosts Weight Loss and Hormonal Balance in PCOS, Study Finds
A new study in Nature Medicine reveals intermittent fasting may aid weight loss and improve hormonal imbalances in women with polycystic ovary syndrom...
Artificial Sweeteners vs. Water for Weight Loss: What the Research Shows
A Harvard study found that replacing sugary drinks with artificially sweetened beverages or water can lead to modest weight loss. Experts warn that wh...